UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net income	$ 13,874	$ 16,635	$ 16,473
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	730	623	612
Amortization	2,065	5,692	6,417
Provision for losses on accounts receivable	(4)	(33)	30
Amortization of operating lease assets	51	53	53
Deferred income taxes	(359)	(693)	(401)
Stock-based compensation expense	256	225	183
Tax benefit attributable to exercise of stock options	21	12	6
Accounts receivable	(835)	2,270	(511)
Other receivables	54	0	(14)
Inventories	587	(670)	(2,353)
Prepaid expenses and other current assets	(32)	45	(64)
Accounts payable	(73)	(456)	464
Accrued expenses	(1,504)	(1,422)	252
Net cash provided by operating activities	14,831	22,281	21,147
Cash flows from investing activities
Property and equipment	(230)	(639)	(809)
Intangible assets	(5)	0	(9)
Proceeds from the sale of property and equipment	27	0	0
Net cash (used in) investing activities	(208)	(639)	(818)
Cash flows from financing activities
Proceeds from issuance of common stock - options	390	117	174
Common stock purchased and retired	(19,968)	0	(2,495)
Dividends paid	(4,260)	(4,282)	(3,163)
Net cash (used in) financing activities	(23,838)	(4,165)	(5,484)
Effect of exchange rate changes on cash	(677)	339	(767)
Net increase in cash and cash equivalents	(9,892)	17,816	14,078
Cash at beginning of year	92,868	75,052	60,974
Cash at end of year	82,976	92,868	75,052
Income taxes	4,638	4,827	4,970
Interest	$ 0	$ 0	$ 0